When will poor countries gain access?

Gilead Sciences has recently achieved a significant milestone with the approval of its revolutionary HIV prevention drug in the United States. However, the company now faces the challenge of ensuring that this groundbreaking medicine is accessible in low-income countries where HIV remains a persistent issue.

Gilead is optimistic about its ability to overcome this hurdle, citing existing groundwork that has been laid to make the drug, lenacapavir, available in 120 predominantly low- and lower-middle-income countries. Last October, the drugmaker entered into voluntary licensing agreements that will eventually facilitate the distribution of lenacapavir in these regions. Additionally, collaborative efforts between the President’s Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis, and Malaria have resulted in an arrangement to provide dosing for 2 million individuals over the course of three years in various impoverished countries.

While Gilead’s progress is promising, access to the full article is restricted to STAT+ subscribers. For exclusive access to this content, as well as in-depth analysis, newsletters, premium events, and news alerts, readers are encouraged to subscribe to STAT+. By subscribing, individuals can gain valuable insights into the ongoing efforts to make HIV prevention medication more widely available in low-income countries.